Clinical Trial Update: Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the combination of plerixafor (AMD3100) and bevacizumab for recurrent high-grade glioma has been terminated. The study enrolled patient…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Astrocytoma
• Anaplastic Oligodendroglioma
• Glioblastoma
• Gliosarcoma
• Mixed Oligoastrocytoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Plerixafor (Mozobil) (plerixafor)

Snippet

Sponsor: Patrick Y. Wen, MD | Conditions: High Grade Glioma: Glioblastoma (GBM), High Grade Glioma: Gliosarcoma | Phase 1 | Status: TERMINATED